Nailderm (Terbinafine)

Terbinafine, the active ingredient in Nailderm, is an allylamine antifungal presented as an oral tablet for systemic use. It is indicated for the treatment of fungal nail infections and certain skin infections caused by dermatophytes, and is prescribed for adult patients. GNH USA supplies Nailderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Terbinafine is used to treat fungal infections of the nail and skin caused by dermatophytes, offering a systemic oral option for clinicians.

Onychomycosis: clears the fungal infection of the toenail or fingernail, leading to restoration of nail appearance and prevention of further spread. Dermatophyte skin infections: treats conditions such as tinea corporis, tinea pedis and tinea cruris by eliminating the dermatophyte organisms, relieving itching, scaling and redness. Other superficial fungal infections: may be used for mild cases of cutaneous candidiasis when indicated by a clinician.

Terbinafine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea. - Headache: mild to moderate intensity. - Skin rash: pruritic erythema. - Taste disturbance: dysgeusia or loss of taste. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or hepatitis. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Blood dyscrasias: agranulocytosis or aplastic anemia. - Severe cutaneous adverse reactions: toxic epidermal necrolysis.

Before initiating Terbinafine therapy, clinicians should evaluate patient-specific factors and monitor for potential risks. - Assess liver function: obtain baseline hepatic enzymes and repeat as clinically indicated. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in renal impairment: dose adjustment may be required in severe renal dysfunction. - Monitor for drug interactions: review concomitant medications that affect hepatic metabolism. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine can interact with several medicines, altering its concentration or that of the co‑administered drug.

Major Interactions (Avoid): - Azole antifungals (e.g., itraconazole): increased risk of hepatotoxicity. - Rifampin: induces metabolism, reducing terbinafine plasma levels. - Cimetidine: may raise terbinafine exposure and liver enzyme levels. - Isoniazid: additive hepatic toxicity when combined.

Moderate Interactions (Monitor Closely): - Warfarin: terbinafine may potentiate anticoagulant effect, increasing INR. - Oral contraceptives: reduced efficacy reported, consider alternative contraception. - Antidepressants (SSRIs): possible QT interval prolongation, monitor ECG.